ACOG $ACOGF $ACOG
$ACOG.V closed green @ $1.08 ,mc $66.42M
watching closely at these levels before they meet with the FDA to discuss clinical development in the coming months
Potential for major movement once treatment is FDA approved IMO
so far been progressing successfully in their trials for the ALPHA-1062 Traumatic Brain Injury treatment
the treatment has proven to be neuroprotective in that it promotes brain function and performance as well and neuroplasticity and neurogenesis of brain structure with tramautic injury
in four of five functional measures of recovery, the performance of ALPHA-1062 treated group was statistically indistinguishable from that of the uninjured cohort.